The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.

Autor: Caswell DR; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. deborah.caswell@crick.ac.uk., Gui P; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Mayekar MK; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Law EK; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA., Pich O; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Bailey C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Boumelha J; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK., Kerr DL; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Blakely CM; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Manabe T; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Martinez-Ruiz C; Cancer Genome Evolution Research Group, University College London, Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Bakker B; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., De Dios Palomino Villcas J; Core Research Laboratory, ISPRO, Florence, Italy., I Vokes N; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dietzen M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Genome Evolution Research Group, University College London, Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Angelova M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Gini B; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Tamaki W; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Allegakoen P; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Wu W; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Humpton TJ; p53 and Metabolism Laboratory, The Francis Crick Institute, London, UK.; CRUK Beatson Institute, Glasgow, UK.; Glasgow Caledonian University, Glasgow, UK., Hill W; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Tomaschko M; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK., Lu WT; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Haderk F; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Al Bakir M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Nagano A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Gimeno-Valiente F; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., de Carné Trécesson S; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK., Vendramin R; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Barbè V; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Mugabo M; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Weeden CE; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Rowan A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., McCoach CE; Genentech Inc, South San Francisco, CA, USA., Almeida B; The Roger Williams Institute of Hepatology, Foundation for Liver Research, London, UK.; Faculty of Life Sciences & Medicine, King's College London, London, UK., Green M; Experimental Histopathology, The Francis Crick Institute, London, UK., Gomez C; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Nanjo S; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Barbosa D; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Moore C; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK., Przewrocka J; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Black JRM; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Genome Evolution Research Group, University College London, Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Grönroos E; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Suarez-Bonnet A; Experimental Histopathology, The Francis Crick Institute, London, UK.; Department of Pathobiology & Population Sciences, The Royal Veterinary College, London, UK., Priestnall SL; Experimental Histopathology, The Francis Crick Institute, London, UK.; Department of Pathobiology & Population Sciences, The Royal Veterinary College, London, UK., Zverev C; Biological Research Facility, The Francis Crick Institute, London, UK., Lighterness S; Biological Research Facility, The Francis Crick Institute, London, UK., Cormack J; Biological Research Facility, The Francis Crick Institute, London, UK., Olivas V; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Cech L; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Andrews T; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Rule B; Cursorless, London, UK., Jiao Y; Novogene Europe, Cambridge, UK., Zhang X; Novogene Europe, Cambridge, UK., Ashford P; Institute of Structural and Molecular Biology, University College London, London, UK., Durfee C; Department of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX, USA., Venkatesan S; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Temiz NA; Institute for Health Informatics, University of Minnesota, Minneapolis, MN, USA.; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA., Tan L; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Larson LK; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA., Argyris PP; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.; School of Dentistry, University of Minnesota, Minneapolis, MN, USA.; College of Dentistry, Ohio State University, Columbus, OH, USA., Brown WL; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA., Yu EA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Sutter Health Palo Alto Medical Foundation, Department of Pulmonary and Critical Care, Mountain View, CA, USA., Rotow JK; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Guha U; Thoracic and GI Malignancies Branch, NCI, NIH, Bethesda, MD, USA.; NextCure Inc., Beltsville, MD, USA., Roper N; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yu J; Biomedical Sciences Program, University of California, San Francisco, San Francisco, CA, USA., Vogel RI; Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA., Thomas NJ; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Marra A; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology IRCCS, Milan, Italy., Selenica P; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Yu H; Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Department of Medicine, Weill Cornell College of Medicine, New York City, NY, USA., Bakhoum SF; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Chew SK; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Reis-Filho JS; Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Jamal-Hanjani M; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK.; Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.; Department of Medical Oncology, University College London Hospitals, London, UK., Vousden KH; p53 and Metabolism Laboratory, The Francis Crick Institute, London, UK., McGranahan N; Cancer Genome Evolution Research Group, University College London, Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kanu N; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Harris RS; Department of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX, USA.; Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, TX, USA., Downward J; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK., Bivona TG; Departments of Medicine and Cellular and Molecular Pharmacology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.; Chan Zuckerberg Biohub, San Francisco, CA, USA. trever.bivona@ucsf.edu., Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK.

Publikováno v: Nature genetics [Nat Genet] 2024 Jan; Vol. 56 (1), pp. 60-73. Date of Electronic Publication: 2023 Dec 04.

An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations.

Autor: Boumelha J; Oncogene Biology Laboratory, Francis Crick Institute, London, United Kingdom., de Carné Trécesson S; Oncogene Biology Laboratory, Francis Crick Institute, London, United Kingdom., Law EK; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota.; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota.; Howard Hughes Medical Institute, University of Minnesota, Minneapolis, Minnesota., Romero-Clavijo P; Oncogene Biology Laboratory, Francis Crick Institute, London, United Kingdom., Coelho MA; Oncogene Biology Laboratory, Francis Crick Institute, London, United Kingdom., Ng KW; Retroviral Immunology Laboratory, Francis Crick Institute, London, United Kingdom., Mugarza E; Oncogene Biology Laboratory, Francis Crick Institute, London, United Kingdom., Moore C; Oncogene Biology Laboratory, Francis Crick Institute, London, United Kingdom., Rana S; Oncogene Biology Laboratory, Francis Crick Institute, London, United Kingdom.; Lung Cancer Group, Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom., Caswell DR; Translational Cancer Therapeutics Laboratory, Francis Crick Institute, London, United Kingdom., Murillo M; Oncogene Biology Laboratory, Francis Crick Institute, London, United Kingdom.; Lung Cancer Group, Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom., Hancock DC; Oncogene Biology Laboratory, Francis Crick Institute, London, United Kingdom., Argyris PP; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota.; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota.; Howard Hughes Medical Institute, University of Minnesota, Minneapolis, Minnesota.; Division of Oral and Maxillofacial Pathology, School of Dentistry, University of Minnesota, Minneapolis, Minnesota., Brown WL; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota.; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota., Durfee C; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota.; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota.; Department of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, Texas., Larson LK; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota.; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota., Vogel RI; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.; Department of Obstetrics, Gynecology, and Women's Health, University of Minnesota, Minneapolis, Minnesota., Suárez-Bonnet A; Experimental Histopathology, Francis Crick Institute, London, United Kingdom.; Department of Pathobiology and Population Sciences, Royal Veterinary College, Hatfield, United Kingdom., Priestnall SL; Experimental Histopathology, Francis Crick Institute, London, United Kingdom.; Department of Pathobiology and Population Sciences, Royal Veterinary College, Hatfield, United Kingdom., East P; Bioinformatics and Biostatistics, Francis Crick Institute, London, United Kingdom., Ross SJ; AstraZeneca Oncology R&D, Cambridge, United Kingdom., Kassiotis G; Retroviral Immunology Laboratory, Francis Crick Institute, London, United Kingdom., Molina-Arcas M; Oncogene Biology Laboratory, Francis Crick Institute, London, United Kingdom., Swanton C; Translational Cancer Therapeutics Laboratory, Francis Crick Institute, London, United Kingdom., Harris R; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota.; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota.; Howard Hughes Medical Institute, University of Minnesota, Minneapolis, Minnesota.; Department of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, Texas.; Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, Texas., Downward J; Oncogene Biology Laboratory, Francis Crick Institute, London, United Kingdom.; Lung Cancer Group, Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.

Publikováno v: Cancer research [Cancer Res] 2022 Oct 04; Vol. 82 (19), pp. 3435-3448.

MagnEdit-interacting factors that recruit DNA-editing enzymes to single base targets.

Autor: McCann JL; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.; Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA.; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.; Center for Genome Engineering, University of Minnesota, Minneapolis, MN, USA.; Howard Hughes Medical Institute, University of Minnesota, Minneapolis, MN, USA., Salamango DJ; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.; Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA.; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.; Center for Genome Engineering, University of Minnesota, Minneapolis, MN, USA., Law EK; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.; Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA.; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.; Center for Genome Engineering, University of Minnesota, Minneapolis, MN, USA.; Howard Hughes Medical Institute, University of Minnesota, Minneapolis, MN, USA., Brown WL; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.; Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA.; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.; Center for Genome Engineering, University of Minnesota, Minneapolis, MN, USA., Harris RS; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA rsh@umn.edu.; Institute for Molecular Virology, University of Minnesota, Minneapolis, MN, USA.; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.; Center for Genome Engineering, University of Minnesota, Minneapolis, MN, USA.; Howard Hughes Medical Institute, University of Minnesota, Minneapolis, MN, USA.

Publikováno v: Life science alliance [Life Sci Alliance] 2020 Feb 24; Vol. 3 (4). Date of Electronic Publication: 2020 Feb 24 (Print Publication: 2020).

The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of Cyclin D1.

Autor: McCann JL; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota 55455; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota 55455; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota 55455., Klein MM; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota 55455., Leland EM; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota 55455., Law EK; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota 55455; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota 55455; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota 55455; Howard Hughes Medical Institute, University of Minnesota, Minneapolis, Minnesota 55455., Brown WL; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota 55455; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota 55455; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota 55455., Salamango DJ; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota 55455; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota 55455; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota 55455. Electronic address: dsalaman@umn.edu., Harris RS; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota 55455; Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota 55455; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455; Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota 55455; Howard Hughes Medical Institute, University of Minnesota, Minneapolis, Minnesota 55455. Electronic address: rsh@umn.edu.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2019 Aug 09; Vol. 294 (32), pp. 12099-12111. Date of Electronic Publication: 2019 Jun 19.

Polyomavirus T Antigen Induces APOBEC3B Expression Using an LXCXE-Dependent and TP53-Independent Mechanism.

Autor: Starrett GJ; Department of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA., Serebrenik AA; Department of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA., Roelofs PA; Department of Radiation Oncology, Radiotherapy and OncoImmunology Laboratory, Radboud University Medical Center, Nijmegen, The Netherlands., McCann JL; Department of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA., Verhalen B; Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA., Jarvis MC; Department of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA., Stewart TA; Department of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA., Law EK; Department of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA., Krupp A; Department of Neuroimmunology, Biogen, Cambridge, Massachusetts, USA., Jiang M; Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA., Martens JWM; Department of Medical Oncology, Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Cahir-McFarland E; Department of Neuroimmunology, Biogen, Cambridge, Massachusetts, USA., Span PN; Department of Radiation Oncology, Radiotherapy and OncoImmunology Laboratory, Radboud University Medical Center, Nijmegen, The Netherlands., Harris RS; Department of Biochemistry, Molecular Biology and Biophysics, Masonic Cancer Center, Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota, USA rsh@umn.edu.; Howard Hughes Medical Institute, University of Minnesota, Minneapolis, Minnesota, USA.

Publikováno v: MBio [mBio] 2019 Feb 05; Vol. 10 (1). Date of Electronic Publication: 2019 Feb 05.